Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26865302 | 0.85 | HTT (0.45) | ALDH1A1KMT2AMEN1HTTGAA | |
| SCHEMBL10153776 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2FDPS | |
| SCHEMBL6298490 | 0.79 | FDPS (0.44) | ALDH1A1KMT2AMEN1FDPSPKM | |
| SCHEMBL6254715 | 0.77 | CTSK (0.41) | ALDH1A1POLBSMN1; SMN2FDPSHPGD | |
| SCHEMBL291399 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL4574427 | 0.76 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL28011812 | 0.76 | FDPS (0.46) | ALDH1A1KMT2AMEN1FDPSPKM | |
| SCHEMBL992041 | 0.74 | FDPS (0.44) | ALDH1A1FDPSHPGDTSHR | |
| SCHEMBL12530273 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL14257698 | 0.73 | FDPS (0.43) | ALDH1A1FDPSPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | ALDH1A1 802/4885KMT2A 23/4885MEN1 3491/4885 |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | ALDH1A1 802/4885KMT2A 23/4885MEN1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.